Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia.
Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia.
复制标题
肠道微生物群和微生物相关代谢物对高脂血症的影响。
DOI：
10.3389/fcimb.2021.634780
复制
发表时间：
2021
影响因子：
5.7
通讯作者：
Wu S
中科院分区：
文献类型：
--
作者：
Jia X;Xu W;Zhang L;Li X;Wang R;Wu S
高血压，定义为血液中存在过量脂肪或脂质，已被认为是许多代谢疾病的高危因素和关键指标。肠道微生物群在调节宿主脂质代谢中起着重要作用。通过无菌小鼠粪便菌群移植实验，揭示了肠道菌群在高脂血症发生发展中的致病作用。微生物群相关代谢产物如胆汁酸、脂多糖和短链脂肪酸在高脂血症调节中的效应机制已部分揭示。此外，针对肠道微生物群的高脂血症干预措施的研究，包括使用益生元，益生菌，粪便微生物群移植和天然草药，也显示了其治疗高脂血症的疗效。本文综述了肠道菌群与高脂血症的关系、肠道菌群及其代谢产物对高脂血症发生发展的影响以及针对肠道菌群的高脂血症治疗策略。
Hyperlipidemia, defined as the presence of excess fat or lipids in the blood, has been considered as a high-risk factor and key indicator of many metabolic diseases. The gut microbiota has been reported playing a vital role in regulating host lipid metabolism. The pathogenic role of gut microbiota in the development of hyperlipidemia has been revealed through fecal microbiota transplantation experiment to germ-free mice. The effector mechanism of microbiota-related metabolites such as bile acids, lipopolysaccharide, and short-chain fatty acids in the regulation of hyperlipidemia has been partially unveiled. Moreover, studies on gut-microbiota-targeted hyperlipidemia interventions, including the use of prebiotics, probiotics, fecal microbiota transplantation, and natural herbal medicines, also have shown their efficacy in the treatment of hyperlipidemia. In this review, we summarize the relationship between gut microbiota and hyperlipidemia, the impact of gut microbiota and microbiota-related metabolites on the development and progression of hyperlipidemia, and the potential therapeutic management of hyperlipidemia targeted at gut microbiota.